Masakazu Fukushima

This inventor holds 43 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Hitachi, Ltd., Taiho Pharmaceutical Company Limited, Nippon Hoso' Kyokai. Active years: 1979-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masakazu Fukushima. Retrieved from https://idiyas.com/inventor/masakazu-fukushima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 43 (Patent Applications = 2)

% Patents Active = 90.7

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 3.1

ph-index = 9

Forward Citations = 297(Granted Patents)

Location History:

Kokubunji, JP (1979 - 1984)
Hinode, JP (1987)
Nishitama, JP (1989 - 1992)
Hannou, JP (1996 - 2003)
Hanno, JP (1998 - 2003)
Tokushima, JP (2011 - 2013)
Shiga, JP (2014)
Otsu, JP (1992 - 2018)
Tokyo, JP (1984 - 2019)

Company Filing History:

Taiho Pharmaceutical Company Limited

Delta-Fly Pharma, Inc.

patents

5. 2 out of 208

Hitachi Denshi Kabushiki Kaisha

patents

6. 2 out of 217

Hitachi Device Engineering Co., Ltd.

patents

7. 1 out of 846

Otsuka Pharmaceutical Company, Limited

patents

8. 1 out of 212

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

patents

9. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1979-2019

Loading Chart...

Areas of Expertise:

Antitumor Agents

HIV Treatments

Radiation Therapy

Uracil Derivatives

Thiazolidinedione Derivatives

Electrostatic Deflection

Image Pickup Tubes

Electron Guns

Charged-Particle Beams

Topical Administration

Assay Kits

Monoclonal Antibodies

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE47388 - Agents for alleviating side effects (2019-05-13),

2. 10111955 - PEG derivative (2018-10-30),

3. 9855345 - Method for producing lipoplex for topical administration and antitumor agent using such lipoplex (2018-01-02),

4. 8889699 - 5-fluorouracil derivative (2014-11-18),

5. 8569324 - Potentiator for radiation therapy comprising pyridine derivative as active ingredient (2013-10-29),

6. 8440675 - Potentiator of radiation therapy (2013-05-14),

7. 8148381 - Potentiator of radiation therapy (2012-04-03),

8. 8058261 - 3'-ethynylcytidine derivative (2011-11-15),

9. 6596720 - Anti-HIV compositions (2003-07-22),

10. 6569634 - Method for assaying human thymidylate synthase and assay kit (2003-05-27),

11. 6566582 - Animals with insufficient expression of uridine phosphorylase (2003-05-20),

12. 6500932 - Antihuman thymidylate synthase monoclonal antibodies and hybridomas producing the same (2002-12-31),

13. 6479500 - Agents for alleviating side effects (2002-11-12),

14. 6294535 - Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same (2001-09-25),

15. 6160017 - Preventives and remedies for ulcerous colitis and/or crohn's disease (2000-12-12),

Title: **Masakazu Fukushima: A Pioneer in Cancer Treatment Innovation**

Introduction

Masakazu Fukushima, based in Tokyo, Japan, is a distinguished inventor known for his significant contributions to cancer treatment through innovative pharmaceutical compounds. With an impressive portfolio of 43 patents, Fukushima has dedicated his career to developing novel agents that alleviate the side effects of anti-tumor treatments, thereby improving the quality of life for patients undergoing chemotherapy.

Latest Patents

Fukushima's latest innovations include agents designed to alleviate side effects caused by anti-tumor agents. One of his notable inventions is a compound formulated to reduce inflammation in the digestive tract, effectively addressing symptoms such as diarrhea and weight loss without interfering with the efficacy of chemotherapy. This invention emphasizes the importance of continuing cancer treatment while minimizing patient discomfort. Another recent patent introduces a new therapeutic agent for malignant tumors, focusing on safety and sustained anti-tumor effects, all while enhancing the administration methods and frequency of treatment.

Career Highlights

Fukushima has made substantial impacts in the pharmaceutical industry, working with renowned companies such as Hitachi, Ltd. and Taiho Pharmaceutical Company Limited. His work in these organizations has contributed to the advancement of cancer therapies that not only target tumors but also consider the overall well-being of patients.

Collaborations

Throughout his career, Masakazu Fukushima has collaborated with esteemed professionals, including Masanori Maruyama and Shingo Yano. These collaborations have fostered an environment of innovation and have led to the successful development of several groundbreaking patents aimed at improving cancer treatment.

Conclusion

Masakazu Fukushima stands out as a pivotal figure in the field of cancer treatment innovation. His extensive patent portfolio and collaborations demonstrate his commitment to developing effective solutions that enhance patient care. As research and development in oncology continue to evolve, Fukushima’s contributions will undoubtedly play a crucial role in shaping future therapeutic strategies.

Profile summary based on public USPTO records.